117P Immunoprofile of adenosquamous carcinoma in gastric cancer

Wu, Cheng‐Hsien; Lai, C-L.; Teng, C-L.; Fang, W-L.; Huang, Kuo‐How; Li, F-Y.; Chao, Y.; Hung, Y-P.; Mh, Chen

doi:10.1016/j.annonc.2022.10.153

Cited by 4 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…al. demonstrated that, compared to other histological subtypes, gastric ASC has a higher proportion of positive surrogate biomarkers in immunotherapy (11). Thus, immunotherapy may be a treatment of choice for patients with gastric ASC, especially for those with a high positivity rate of prediction markers in the tumor (11).…”

Section: Discussion Discussionmentioning

confidence: 99%

Adenosquamous Carcinoma of the Stomach in a Caucasian Man: A Case Report

Vieira Sousa,

Pereira,

Barbosa

et al. 2024

SGO

View full text Add to dashboard Cite

Introduction: In all pathologic types of gastric cancer, adenocarcinoma is the most common, whereas the incidence of adenosquamous carcinoma (ASC) remains extremely low, accounting for less than 1% of total gastric malignancies. Due to the rarity of ASC, limited data are available to conclude the histogenesis, clinicopathologic characteristics, optimal treatment strategies, and prognosis. This rare clinical entity exhibits a higher prevalence in men, particularly in Asians, and typically manifests at advanced stages. Case report: In this report, we describe the case of an 88-year-old Caucasian man, an ex-smoker with chronic alcohol abuse and high-grade urothelial carcinoma, who developed upper gastrointestinal bleeding and anemia in December 2021. Upper gastrointestinal endoscopy revealed an ulcer-vegetative lesion next to the pylorus, confirmed pathologically as gastric carcinoma. A staging thoracic-abdominopelvic computed tomography scan excluded distant metastatic disease or other suspicious lesions. In February 2022, he underwent a sub-total distal gastrectomy with a Billroth type-2 anastomosis without complications. In the postoperative period, he developed pneumonia from which he recovered with antibiotics. The pathological examination identified an ulcer-infiltrative lesion in the antrum, infiltrating the gastric wall to the serosal layer, classifying it as a gastric adenosquamous carcinoma (pT4aN0R0). Conclusion: ASC represents a rare histological type of gastric carcinoma, especially in Western populations. The etiopathogenesis of this tumor remains incompletely understood and has a poor prognosis because presents at advanced staging and with frequent venous and lymphatic invasion. So, clinicians should be aware of this type of gastric carcinoma so as not to delay diagnosis and treatment, reducing survival.

show abstract

Section: Discussion Discussionmentioning

confidence: 99%

Adenosquamous Carcinoma of the Stomach in a Caucasian Man: A Case Report

Vieira Sousa,

Pereira,

Barbosa

et al. 2024

SGO

View full text Add to dashboard Cite

show abstract

“…and considering immunotherapy as frontline systemic treatment for GASC. 8 The molecular pathogenesis of GASC is poorly understood. In 2000, Woo et al 9 studied microsatellite instability (MSI) caused by defective DNA mismatch repair (MMR) in gastric carcinomas with squamous differentiation.…”

mentioning

confidence: 99%

“…In the study titled “Immunoprofile of adenosquamous carcinoma in gastric cancer,” Wu et al 8 investigated the clinical features, treatment outcomes, and immunoprofile of GASC to determine the optimal treatment modality for these patients. The authors retrospectively reviewed patients with GASC from a single institute and analyzed their clinical data and tumor samples.…”

mentioning

confidence: 99%

“…It highlights the importance of examining biomarkers and considering immunotherapy as frontline systemic treatment for GASC. 8…”

mentioning

confidence: 99%

“…Overall, Wu et al 8 provide valuable insights into the clinical characteristics, treatment outcomes, and immunoprofile of GASC. It emphasizes the potential role of immunotherapy in the management of GASC patients and suggests the need for further research in this area.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Understanding gastric adenosquamous cell carcinoma: Insights from immunoprofiling

Liu

2023

Journal of the Chinese Medical Association

View full text Add to dashboard Cite

Gastric adenosquamous cell carcinoma (GASC), like other adenosquamous cell carcinomas of the digestive system, is a rare histological subtype with aggressive tumor behavior. 1 Recent literature has focused on characterizing the clinicopathological features and distinct clinical outcomes compared to its adenocarcinoma counterpart. While some studies have reported the lower third of the stomach as the most common site for adenosquamous cell carcinoma, 2,3 larger registry database studies have reported a higher frequency in the gastric cardia (upper third). 4,5 Poor differentiation is a common tendency, 4-6 and the presence of a squamous component appears to contribute to a poor prognosis. 7 In the study titled "Immunoprofile of adenosquamous carcinoma in gastric cancer," Wu et al 8 investigated the clinical features, treatment outcomes, and immunoprofile of GASC to determine the optimal treatment modality for these patients. The authors retrospectively reviewed patients with GASC from a single institute and analyzed their clinical data and tumor samples. The study found that the median tumor size in stage III GASC patients was 6.8 cm, and all of these patients underwent radical gastrectomy followed by adjuvant therapy. The median progression-free survival (PFS) and overall survival (OS) for stage III GASC patients were 6.0 and 11.5 months, respectively. Two patients with stage IV GASC received frontline immunotherapy, with a median PFS and OS of 9.0 and 12.5 months, respectively. Immunoprofiling of the GASC samples revealed that 25% of the samples had deficient mismatch repair (dMMR) protein, 75% had a combined positive score (CPS) of ≥1, and 33.3% had a CPS of ≥10. The study also found that programmed death-ligand 1 expression of ≥5% was significantly associated with superior OS. One stage IV patient with CPS ≥10 and dMMR proteins received nivolumab monotherapy as frontline treatment, resulting in a PFS of 14 months. The study suggests that patients with GASC are more likely to exhibit positive results for CPS and dMMR. It highlights the importance of examining biomarkers

show abstract

Winners of the 2023 honor awards for excellence at the annual meeting of the Chinese Medical Association-Taipei: Part I

Wang,

Yang

2024

Journal of the Chinese Medical Association

View full text Add to dashboard Cite

The present editorial is a "Part I," focusing on the recent advance of cancer treatment. 1,[6][7][8][9][10] Conventionally, treatment opinions have limited to surgery, radiotherapy, and chemotherapy before. Although the majority of them, if localized tumor or early-stage cancers are diagnosed, can be successfully managed by three aforementioned strategies, there is no doubt that for a substantial number of women presenting with persistent, recurrent and/or metastatic cancers the prognosis is extremely poor, and rarely these advanced cancer patients could have the median overall survival more than 1 year, suggesting that new prognostic information-or personalized biomarkers-driven approach treatment is urgently needed.Herein, we are happy to introduce the exciting works from the "Winners" of the 2023 honor awards for excellence at the annual meeting of the Chinese Medical Association-Taipei. In this part I, Dr. Wu and his colleagues won this award for their work entitled "Immunoprofile of adenosquamous carcinoma in gastric cancer" which was published in the June issue of 2023 JCMA. 1 The authors attempted to investigate the immune profile of the rare subtype of gastric cancer in Taiwan to look for the optimal treatment modality. Among the data pool of all gastric cancers, gastric adenosquamous cancer (GASC) presented 0.35% (14/4034) reflecting its real rarity. Their study protocols included the recently very important biomarkers, such as p40, human epidermal growth factor receptor 2 (HER2), Epstein-Barr virus-encoded RNA (EBER), programmed death-ligand 1 (PD-L1) combined positive score (CPS), V-Raf murine sarcoma viral oncogene homolog B (BRAF), and DNA mismatch repair (MMR) proteins (eg, MutL Homolog 1 [MLH1], MutS homolog

show abstract

117P Immunoprofile of adenosquamous carcinoma in gastric cancer

Cited by 4 publications

References 0 publications

Adenosquamous Carcinoma of the Stomach in a Caucasian Man: A Case Report

Adenosquamous Carcinoma of the Stomach in a Caucasian Man: A Case Report

Understanding gastric adenosquamous cell carcinoma: Insights from immunoprofiling

Winners of the 2023 honor awards for excellence at the annual meeting of the Chinese Medical Association-Taipei: Part I

Contact Info

Product

Resources

About